This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
Last week I tweeted:
I received varied response, Pascale Lane and Michael Katz agreed, while Dr. Canapari disagreed:
And Matt Sparks called me directly to tell me that I was crazy; the analytics he has access to show search by a mile.
Here is the data for the last month at NephJC, Direct links (bookmarks, e-mail links, hand typed URLs, others?, etc) and Twitter (t.co) represent 75% of traffic with Google mopping up a distant third.
Good turnout with 25 people and 264 tweets.
We had a great NephJC last week going over the meta analysis on troponin in CKD> Meta analysis are hard to do in journal club, but it was a great session. Lots of new faces.
Some very clever people have asked me how to embed a Storify into a blog post. Here are some step by step instructions.
The eAJKD crew and Tejas Desai both storified last night's twitter NephJC. Dig in:
It was a fine evening for discussion. Despite (or perhaps because of) the recent #UroJC which was just concluding, we had a good turnout and some great discussion.
The UroJC started their Twitter JC is stunning fashion yesterday. Here is my storify complete with sarcastic comments.
This just came through today:
This means we now have analytics from their excellent September 10 Tweetchat. It is very cool that Symplur was able to provide analytics going that far back. Bravo. Great work.
Twitter is a strange a service, because if you don't follow anyone it is about as useful as the first telephone. Value only emerges as your follow list evolves. One of the missions of NephJC is to bring nephrologists together for twitter events so people can find other interesting people develop there own network. If you don't pick up 1 or 2 new people to follow at every #NephJC discussion either we are doing a bad job or you're doing it wrong.
The value of Twitter is related directly to the quality of the people you follow. In the spirit of helping people get started on Twitter we are going to recommend accounts to follow on Twitter. This first edition is about official accounts.
CRIC: Chrinic Renal Insufficiency Cohort. The most important observational study in CKD ever conducted.
KDIGO: Global nephrology clinical practice guidelines
ERA-EDTA: European nephrology professional association
ASNKidney: The big kahuna.
RenalMed: Free online nephrology resources
NatureRevNephrology: Editors of Nature Reviews Nephrology
Andrew Narva: Director of of the NKDEP using twitter to fight the good fight
Richard Lehman: Simply the best commentator on internal medicine research in the world.
Kidney News: News magazine for the ASN
NEJM: The Journal of Record
JAMA: Wants to be The Journal of Record
CJASN: New to the show, show them some follow love. Only 22 followers. Really?
eAJKD: the blog of the AJKD with 1200 followers. Hey, CJASN, this is how it's done!
The International Society of Nephrology. ASN but for the world.
Canadian Society of Nephrology. ASN but for the Great White North
